258 related articles for article (PubMed ID: 19299069)
1. Tumour grade, treatment, and relative survival in a population-based cohort of men with potentially curable prostate cancer.
Ladjevardi S; Sandblom G; Berglund A; Varenhorst E
Eur Urol; 2010 Apr; 57(4):631-8. PubMed ID: 19299069
[TBL] [Abstract][Full Text] [Related]
2. Editorial comment on: tumour grade, treatment, and relative survival in a population-based cohort of men with potentially curable prostate cancer.
Gallina A
Eur Urol; 2010 Apr; 57(4):639. PubMed ID: 19299073
[No Abstract] [Full Text] [Related]
3. Editorial comment on: tumor grade, treatment, and relative survival in a population-based cohort of men with potentially curable prostate cancer.
Yossepowitch O
Eur Urol; 2010 Apr; 57(4):639-40. PubMed ID: 19299071
[No Abstract] [Full Text] [Related]
4. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.
Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849
[TBL] [Abstract][Full Text] [Related]
5. A competing-risks analysis of survival after alternative treatment modalities for prostate cancer patients: 1988-2006.
Abdollah F; Sun M; Thuret R; Jeldres C; Tian Z; Briganti A; Shariat SF; Perrotte P; Rigatti P; Montorsi F; Karakiewicz PI
Eur Urol; 2011 Jan; 59(1):88-95. PubMed ID: 20965646
[TBL] [Abstract][Full Text] [Related]
6. Mortality among men with locally advanced prostate cancer managed with noncurative intent: a nationwide study in PCBaSe Sweden.
Akre O; Garmo H; Adolfsson J; Lambe M; Bratt O; Stattin P
Eur Urol; 2011 Sep; 60(3):554-63. PubMed ID: 21664039
[TBL] [Abstract][Full Text] [Related]
7. Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence.
Boorjian SA; Thompson RH; Tollefson MK; Rangel LJ; Bergstralh EJ; Blute ML; Karnes RJ
Eur Urol; 2011 Jun; 59(6):893-9. PubMed ID: 21388736
[TBL] [Abstract][Full Text] [Related]
8. The role of overall treatment time in the outcome of radiotherapy of prostate cancer: an analysis of biochemical failure in 4839 men treated between 1987 and 1995.
Thames HD; Kuban D; Levy LB; Horwitz EM; Kupelian P; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A
Radiother Oncol; 2010 Jul; 96(1):6-12. PubMed ID: 20400191
[TBL] [Abstract][Full Text] [Related]
9. Careful selection and close monitoring of low-risk prostate cancer patients on active surveillance minimizes the need for treatment.
Soloway MS; Soloway CT; Eldefrawy A; Acosta K; Kava B; Manoharan M
Eur Urol; 2010 Dec; 58(6):831-5. PubMed ID: 20800964
[TBL] [Abstract][Full Text] [Related]
10. A retrospective study of the treatment of locally advanced prostate cancer by six institutions in eastern and north-eastern Japan.
Hachiya T; Akakura K; Saito S; Shinohara N; Sato K; Harada M; Kato T; Okada K
BJU Int; 2005 Mar; 95(4):534-40. PubMed ID: 15705075
[TBL] [Abstract][Full Text] [Related]
11. Further support for active surveillance in the management of low-volume, low-grade prostate cancer.
Albertsen P
Eur Urol; 2010 Dec; 58(6):836-7. PubMed ID: 20851512
[No Abstract] [Full Text] [Related]
12. Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study.
Nieder AM; Porter MP; Soloway MS
J Urol; 2008 Nov; 180(5):2005-9; discussion 2009-10. PubMed ID: 18801517
[TBL] [Abstract][Full Text] [Related]
13. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome.
Ward JF; Slezak JM; Blute ML; Bergstralh EJ; Zincke H
BJU Int; 2005 Apr; 95(6):751-6. PubMed ID: 15794776
[TBL] [Abstract][Full Text] [Related]
14. Prostate-specific antigen control with low-dose adjuvant radiotherapy for high-risk prostate cancer.
Macdonald OK; Lee RJ; Snow G; Lee CM; Tward JD; Middleton AW; Middleton GW; Sause WT
Urology; 2007 Feb; 69(2):295-9. PubMed ID: 17320667
[TBL] [Abstract][Full Text] [Related]
15. Treatment of localised prostate cancer: inform patients about adverse effects.
Prescrire Int; 2012 Oct; 21(131):247. PubMed ID: 23185851
[No Abstract] [Full Text] [Related]
16. Global update on defining and treating high-risk localized prostate cancer with leuprorelin: a USA perspective--identifying men at diagnosis who are at high risk of prostate cancer death after surgery or radiation therapy.
D'Amico A
BJU Int; 2007 Jan; 99 Suppl 1():13-6; discussion 17-8. PubMed ID: 17229162
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of androgen deprivation therapy in prolonging survival of older men treated for locoregional prostate cancer.
Holmes L; Chan W; Jiang Z; Du XL
Prostate Cancer Prostatic Dis; 2007; 10(4):388-95. PubMed ID: 17486111
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of radical prostatectomy in clinically locally advanced N0M0 prostate cancer.
Mearini L; Zucchi A; Costantini E; Bini V; Nunzi E; Porena M
Urol Int; 2010; 85(2):166-72. PubMed ID: 20558980
[TBL] [Abstract][Full Text] [Related]
19. Pretreatment prostate-specific antigen velocity and the risk of death from prostate cancer in the individual with low-risk prostate cancer.
D'Amico AV; Chen MH
J Clin Oncol; 2009 Aug; 27(22):3575-6. PubMed ID: 19506151
[No Abstract] [Full Text] [Related]
20. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T
Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
